Results 191 to 200 of about 27,323 (260)

Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis

American Journal of Hematology, Volume 101, Issue 8, Page 1928-1937, August 2026.
ABSTRACT Talquetamab is a GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). This is the first real‐world study to comprehensively report muco‐cutaneous toxicities, infections, and efficacy of talquetamab in 151 patients across five countries with the longest follow‐up reported enabling better efficacy and ...
Murali Janakiram, Carlyn R. Tan, Hira Mian, Chiung‐Yu Huang, Rakesh Popat, Joaquín Martínez‐Lopez, Efsthathios Kastritis, Wee‐Joo Chng, Prashant Kapoor, Mrugakshi Dave, Susan Bal, Laurent Garderet, Andre De Menezes Silva Corraes, Christine Riedhammer, Torsten Steinbrunn, Magdalene Corona, Chandramouli Nagarajan, Hermann Einsele, Tom Martin, Amrita Krishnan, Yi Lin, Nadine Abdullah, Niels Abildgaard, Ingerid Abrahamsen, Melissa Alsina, Kenneth Anderson, Hervé Avet‐Loiseau, Ashraf Badros, Nizar Jacques Bahlis, Susan Bal, Rahul Banerjee, Dina Ben‐Yehuda, Jesús G. Berdeja, Michele Cavo, Ajai Chari, Wen‐Ming Chen, Marta Chesi, Wee‐Joo Chng, Yael Cohen, Adam Cohen, Gordon Cook, Luciano Costa, Andrew Cowan, Carlos Fernández de Larrea, Benjamin Derman, Juan Du, Hermann Einsele, Gösta Gahrton, Francesca Gay, Sergio A. Giralt, Simon Harrison, J Jean‐Luc Harousseau, Joy Ho, Doris Hansen, Maung Myo Htut, Andrzej J. Jakubowiak, Murali Janakiram, Prashant Kapoor, Efstathios Kastritis, Jonathan Kaufman, Kihyun Kim, Amrita Krishnan, Shaji Kumar, Chara Kyriakou, Xavier Leleu, Yi Lin, Sagar Lonial, Matthew frigault, Johan L. Lund, Elias Mai, Angelo Maiolino, Elias Mai, Angelo Maiolino, Sireesha Asoori Maringanti, Thomas Martin, Joaquin Martinez‐Lopez, María‐Victoria Mateos, Giampaolo Merlini, Hira Mian, Joseph Mikhael, Monique Minnema, Philippe Moreau, Gareth Morgan, Nikhil Munshi, Omar Nadeem, Chandramouli Nagarajan, Ajay Nooka, Michael O'Dwyer, Rimke Oostvogel, Alberto Orfao, Paula Rodriguez Otero, Darren Pan, Krina Patel, Rashesh Popat, Noemí Puig   +94 more
wiley   +1 more source

EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer. [PDF]

J Clin Invest
Fang B, Li X, Lu Y, Ma W, Gan H, Zhang T, Liu Q, Wang B, Wang Z, Zhu Y, Zhu H, Xiao S, Bian X, Wei G, Ye D, Zhu Y.   +15 more
europepmc   +1 more source

CM512, a potentially novel IgG1-based bispecific antibody dual-targeting TSLP and IL-13, for the suppression of type 2 inflammation. [PDF]

J Transl Med
Yang Y, Lan Y, Bian L, Li Y, Song Q, Gao X, Hou Q, Bai Y, Chen B.   +8 more
europepmc   +1 more source

Advances in the Research of Nasopharyngeal Carcinoma: A Perspective

Cancer Innovation, Volume 5, Issue 4, August 2026.
The year 2025 marks a paradigm shift in nasopharyngeal carcinoma management towards greater precision, reduced toxicity, and enhanced intelligence. This review highlights the key breakthroughs from 2025 in clinical trials, technological innovations, and basic research for NPC, offering insights for clinical practice and future investigations.
Zishan Liang, Xian‐Yue Zeng, Jia‐Wei Lv, Guan‐Qun Zhou, Ying Sun, Li Lin   +5 more
wiley   +1 more source

A bispecific antibody designed to act as a NRP2/PLXNA1 agonist mimics anticancer activity of SEMA3F. [PDF]

J Biol Chem
Tian H, Fung CP, Burman L, Chong YE, Liu C, Geng Y, Yang L, Chow MW, Zhang Y, Ho KWH, Zhu G, Wu Z, Yang XL, Xu Z, Nangle LA.   +14 more
europepmc   +1 more source

Comparative Cardiovascular Safety and Exploratory Bleeding Outcomes of Ibrutinib, Acalabrutinib, and Zanubrutinib in Mantle Cell Lymphoma: A Propensity Score‐Matched Real‐World Analysis

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Background Bruton tyrosine kinase inhibitors are central to the treatment of relapsed or refractory mantle cell lymphoma, but cardiovascular and bleeding toxicities influence treatment selection. Ibrutinib has been associated with atrial fibrillation/flutter and other cardiovascular adverse events, whereas second‐generation covalent BTK ...
Anna Homeniuk, Amrit Sandhu, Leena Abdalla, Anas Atrash   +3 more
wiley   +1 more source

First-in-human, phase 1 study of CM512, a TSLP/IL-13 bispecific antibody, in healthy volunteers: safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity. [PDF]

Front Immunol
Cheng Y, Liu Q, Li M, Xie Y, Men Y, He M, Wang H, Feng X, Zeng M, Zhang L, Chen B, Li J, Feng P.   +12 more
europepmc   +1 more source

Harnessing the innate immune system: a novel bispecific antibody targeting CD47 and CD24 for selective tumor clearance. [PDF]

J Immunother Cancer
Nan L, Chen L, Huang W, Peng S, Wang C, Liao H, Wang Y, Cui Z, Lv Y, Wang X, Luo Y, Tsun A, Miao X, Zhang J.   +13 more
europepmc   +1 more source

Correction: Bispecific antibody for lung cancer: mechanisms and clinical insights. [PDF]

Front Immunol
Chen W, Zhou A, Zhou Y.
europepmc   +1 more source

A Bispecific Antibody Blocking Both TSLP and IL-4Rα for the Treatment of Allergic Inflammatory Diseases. [PDF]

Cells
Yu M, Chen P, Jin Y, Huang S, Jiang H, Zhou F, Chiu ML, Zhang D.   +7 more
europepmc   +1 more source